
	Richard C. Christopher joined Caliber I.D. as Chief Financial Officer in March 2014. Previously, he served for eight years as Chief Financial Officer of DUSA Pharmaceuticals, Inc., a vertically integrated specialty dermatology company focused primarily on the development and marketing of its Levulan&reg; Photodynamic Therapy technology platform for the treatment of precancerous skin lesions. Mr. Christopher arrived at DUSA in 2000 and held a series of positions of increasing responsibility before assuming the CFO role in January 2005. He was instrumental in migrating this publicly traded company from operational infancy, through commercialization and profitability, to its eventual sale. In December 2012, he oversaw the sale of DUSA Pharmaceuticals to Sun Pharmaceuticals for $230 million, a 38 percent premium to market. Mr. Christopher holds a masters of science degree in accounting from Suffolk University in Boston and a bachelor of science degree in finance from Bentley College in Waltham, Massachusetts.
